| scholarly article | Q13442814 |
| P356 | DOI | 10.2337/DC06-0997 |
| P698 | PubMed publication ID | 16873829 |
| P50 | author | Jeffrey A Johnson | Q38802305 |
| Paul J Veugelers | Q61784823 | ||
| P2093 | author name string | Sumit R Majumdar | |
| Samantha L Bowker | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 1990-1991 | |
| P577 | publication date | 2006-08-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider | |
| P478 | volume | 29 |
| Q38758615 | A New Role for an Old Drug: Metformin Targets MicroRNAs in Treating Diabetes and Cancer |
| Q37710823 | A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis |
| Q46063551 | A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer |
| Q33789079 | AMPK as a metabolic tumor suppressor: control of metabolism and cell growth |
| Q38668351 | Active targeting co-delivery system based on hollow mesoporous silica nanoparticles for antitumor therapy in ovarian cancer stem-like cells |
| Q41162185 | Alteration of cellular metabolism in cancer cells and its therapeutic prospects |
| Q24655078 | Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease |
| Q36021012 | Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells |
| Q41982167 | Can metabolic plasticity be a cause for cancer? Warburg-Waddington legacy revisited. |
| Q26823118 | Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies |
| Q57810908 | Designed Functional Dispersion for Insulin Protection from Pepsin Degradation and Skeletal Muscle Cell Proliferation: In Silico and In Vitro Study |
| Q48146168 | Diabetes Mellitus and Risk of Hepatocellular Carcinoma. |
| Q58699847 | Diabetes Mellitus is a Risk Factor for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection in China |
| Q33759594 | Diabetes and cancer: Associations, mechanisms, and implications for medical practice |
| Q40699186 | Diabetes mellitus as a prognostic marker in oropharyngeal and laryngeal squamous cell carcinoma |
| Q37737320 | Diabetes mellitus increases the risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis C patients in China |
| Q41842666 | Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? |
| Q33778107 | ERGO: a pilot study of ketogenic diet in recurrent glioblastoma |
| Q55177909 | Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis. |
| Q35511314 | Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer |
| Q39043221 | Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle |
| Q37247194 | Effects of sulfonylureas on tumor growth: a review of the literature |
| Q92662056 | Exploring the bi-directional relationship between pancreatic cancer and diabetes mellitus: a retrospective study |
| Q34654807 | Glipizide, an antidiabetic drug, suppresses tumor growth and metastasis by inhibiting angiogenesis |
| Q46099484 | Glucose metabolism disorders in cancer patients in a Chinese population |
| Q37525828 | Glucose promotes breast cancer aggression and reduces metformin efficacy. |
| Q33499119 | Histological evaluation of AMPK signalling in primary breast cancer |
| Q33690094 | Impact of diabetes mellitus on the outcome of pancreatic cancer |
| Q42363595 | In vitro and in vivo targeting of bladder carcinoma with metformin in combination with cisplatin |
| Q64079227 | Induction of Apoptosis by a Combination of 2-Deoxyglucose and Metformin in Esophageal Squamous Cell Carcinoma by Targeting Cancer Cell Metabolism |
| Q55385002 | Insulin glargine affects the expression of Igf-1r, Insr, and Igf-1 genes in colon and liver of diabetic rats. |
| Q38747245 | Metabolic targets for potential prostate cancer therapeutics |
| Q26823745 | Metabolism and breast cancer risk: frontiers in research and practice |
| Q34135248 | Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders |
| Q47761912 | Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial. |
| Q36896122 | Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. |
| Q54508172 | Metformin interacts with AMPK through binding to γ subunit. |
| Q38674016 | Metformin synergistic pemetrexed suppresses non-small-cell lung cancer cell proliferation and invasion in vitro. |
| Q39707409 | Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner |
| Q35761000 | Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers |
| Q92283963 | Pharmacist-led therapeutic carbohydrate restriction as a treatment strategy for type 2 diabetes: the Pharm-TCR randomized controlled trial protocol |
| Q85111035 | Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer |
| Q38993013 | Prostate Cancer Patients With Unmanaged Diabetes or Receiving Insulin Experience Inferior Outcomes and Toxicities After Treatment With Radiation Therapy |
| Q34040261 | Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway |
| Q41083568 | Recent advances in the use of metformin: can treating diabetes prevent breast cancer? |
| Q44029603 | Retrospective analysis of the effects of steroid therapy and antidiabetic medication on survival in diabetic glioblastoma patients |
| Q34234264 | Risk of cancer in a large cohort of U.S. veterans with diabetes. |
| Q89408597 | Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma |
| Q38096735 | The fat side of prostate cancer |
| Q56978934 | The journey of metformin from glycaemic control to mTOR inhibition and the suppression of tumor growth |
| Q35117423 | Tumor mechanics and metabolic dysfunction |
| Q34357915 | microRNAs and cancer metabolism reprogramming: the paradigm of metformin |
Search more.